Viewing Study NCT00939627


Ignite Creation Date: 2025-12-25 @ 5:06 AM
Ignite Modification Date: 2025-12-26 @ 4:09 AM
Study NCT ID: NCT00939627
Status: COMPLETED
Last Update Posted: 2018-01-23
First Post: 2009-07-14
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Sponsor: National Cancer Institute (NCI)
Organization: